Paliperidone LP-Paliperidone UP

From Psychiatrienet
Revision as of 16:59, 24 February 2023 by Joost (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Paliperidone LP
Xeplion® = long acting, 30 days
Type Antipsychotic
Group Atypical AP
links
PubChem 23724979
PubMed LP%22 Paliperidone LP
Kompas (Dutch) Paliperidone LP
Wikipedia Paliperidone LP
Paliperidone UP
Byannli® = ultra long acting, 178 days
Type Antipsychotic
Group Atypical AP
links
PubChem 23724979
PubMed UP%22 Paliperidone UP
Kompas (Dutch) Paliperidone UP
Wikipedia Paliperidone UP

Switch medication from Paliperidone_LP to Paliperidone_UP.[1] [2]

Nietinrijdenbord.png Stop Paliperidone_LP
  • Day 1: Last depot injection
Eenrichtingbord.png Start Paliperidone_UP

Start depot on the day you would normally have injected the next depot. Determine the dose of paliperidone UP (Byannli ®) by multiplying the dose of paliperidone LP (Xeplion ®) 7 times . Administer every 6 months. [3]


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. Switches are based on information of the KNMP Informatorium medicamentorum: Paliperidone, accessibele at https://www.kennisbank.knmp.nl
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.